Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (603456)
SSE SSE Primary Summary
603456 Chart
People also search for
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (603456) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zhejiang Jiuzhou Pharmaceutical Co., Ltd. ever had a stock split?
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yi Jiang Mei CEO | SSE Exchange | CNE100001W36 ISIN |
| CN Country | 4,877 Employees | 11 Jun 2026 Last Dividend | 12 Apr 2018 Last Split | - IPO Date |
Overview
Zhejiang Jiuzhou Pharmaceutical Co., Ltd, established in 1973, stands as a significant player in the pharmaceutical sector, both within China and on the international stage. The company's headquarters is located in Taizhou, China, underpinning its long-standing legacy and strategic position in the global pharmaceutical industry. Specializing in the manufacture and sale of active pharmaceutical ingredients (API) and intermediates, Zhejiang Jiuzhou Pharmaceutical Co., Ltd leverages extensive research and development to offer a diverse range of pharmaceutical solutions. This commitment has positioned the company as a key supplier in the pharmaceutical value chain, contributing to healthcare globally.
Products and Services
- Active Pharmaceutical Ingredients (API) and Intermediates:
The company's extensive portfolio includes APIs for central nervous system disorders, non-steroidal, anti-infection, antiviral, including those for HCV, antidiabetics, cardiovascular, respiratory anti-infections, tumor treatments, antidepressants, Parkinson's disease, and more. These APIs are crucial components for a variety of medications, embodying the company's commitment to combating a broad spectrum of diseases.
- Asymmetric Catalysts:
As part of its diversified product offering, Zhejiang Jiuzhou Pharmaceutical Co., Ltd provides asymmetric catalysts. These catalysts are essential for the synthesis of certain pharmaceutical compounds, enabling the production of enantiomerically pure drugs. This demonstrates the company's involvement in facilitating advanced synthetic techniques in drug manufacturing.
- Lithium Battery Materials:
Expanding beyond pharmaceuticals, the company also ventures into the production of lithium battery materials. This diversification highlights the company's commitment to contributing to the renewable energy sector, tapping into the growing demand for high-quality materials essential for lithium battery production.
